Table. 2:
The recurrence free and overall survival and the impact of adjuvant therapies.
| Recurrence free survival | Overall survival | |||||
|---|---|---|---|---|---|---|
| 3-year | P=value | 3-year | P=value | |||
| #Patients | n=21* | 78.3% | 85.0% | |||
| Gender | Male | 14 | 68.6% | 0.124 | 78.6% | 0.196 |
| Female | 7 | 100.0% | 100% | |||
| Margin | Negative | 11 | 90.0% | 0.293 | 100% | 0.156 |
| Positive/Close | 10 | 66.7% | 70.0% | |||
| Grade(osteosarcoma) | Low | 3 | 100.0 | 0.201 | 100% | 0.312 |
| High | 15 | 60.8% | 75.0% | |||
| Neo-adjuvant Chemo | No | 13 | 63.5% | 0.031 | 75.0% | 0.066 |
| Yes | 9 | 100.0% | 100% | |||
| Post-operative Chemo | No | 9 | 87.5% | 0.752 | 88.9% | 0.895 |
| Yes | 12 | 71.6% | 81.8% | |||
| Post-operative RT | No | 11 | 70.0% | 0.601 | 80.0% | 0.890 |
| Yes | 12 | 87.5% | 90.0% | |||
*
the patient with non-surgical treatment was not included.